[go: up one dir, main page]

WO2010015260A3 - Administration by infusion for the treatment of ischemic effects - Google Patents

Administration by infusion for the treatment of ischemic effects Download PDF

Info

Publication number
WO2010015260A3
WO2010015260A3 PCT/DK2009/050196 DK2009050196W WO2010015260A3 WO 2010015260 A3 WO2010015260 A3 WO 2010015260A3 DK 2009050196 W DK2009050196 W DK 2009050196W WO 2010015260 A3 WO2010015260 A3 WO 2010015260A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
infusion
receptor agonists
binding
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2009/050196
Other languages
French (fr)
Other versions
WO2010015260A2 (en
Inventor
Uno Jakob Weber
Jacob Gotfredsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROKEY AS
Original Assignee
NEUROKEY AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2008/050293 external-priority patent/WO2009071095A2/en
Application filed by NEUROKEY AS filed Critical NEUROKEY AS
Publication of WO2010015260A2 publication Critical patent/WO2010015260A2/en
Publication of WO2010015260A3 publication Critical patent/WO2010015260A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the induction of hypothermia in humans, male and female, at any age, by use of a pharmaceutical composition to be administered parenterally by infusion or injection, comprising at least one compound selected among (1) vanilloid receptor agonists, capsaicinoids or capsaicinoid-like agonists reaching and binding to vanilloid receptors, and (2) cannabinoids or cannabimimetic agonists reaching and binding to cannabinoid receptors, and (3) adenosine receptor agonists, and (4) neurotensin receptor agonists, and (5) thyroxine derivatives, and (6) cytochrome c inhibitors, and (7) oxygen tension reducers, thereby inducing hypothermia, thus benefiting patients suffering from illnesses characterized by tissue anoxia.
PCT/DK2009/050196 2008-08-07 2009-08-07 Administration by infusion for the treatment of ischemic effects Ceased WO2010015260A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200801079 2008-08-07
DKPA200801079 2008-08-07
DKPCT/DK2008/050293 2008-12-05
PCT/DK2008/050293 WO2009071095A2 (en) 2007-12-05 2008-12-05 Prevention of hyperthermia subsequent to hypothermia treatment of ischemia

Publications (2)

Publication Number Publication Date
WO2010015260A2 WO2010015260A2 (en) 2010-02-11
WO2010015260A3 true WO2010015260A3 (en) 2010-06-17

Family

ID=41168581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2009/050196 Ceased WO2010015260A2 (en) 2008-08-07 2009-08-07 Administration by infusion for the treatment of ischemic effects

Country Status (1)

Country Link
WO (1) WO2010015260A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010027595A1 (en) * 2010-07-23 2012-01-26 Helmut Vorbrüggen Clinical application of adenosine derivative, preferably (dihydroxyphenyl)ethyl-amino-purin-9-yl-(hydroxymethyl)oxolane-diol, for reducing body temperature during impending ischemia of brain vessels, which occur during heart attacks
CA3114582A1 (en) 2010-12-22 2012-06-28 Syqe Medical Ltd. Method and system for drug delivery
US8841292B2 (en) * 2011-08-18 2014-09-23 Weil Institute of Critical Care Medicine Induced hypothermia
EP2764868A1 (en) 2013-02-08 2014-08-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases
CN111557432B (en) 2013-02-08 2023-08-04 通用磨坊公司 Low sodium food
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
PL3160565T3 (en) 2014-06-30 2022-01-10 Syqe Medical Ltd. DEVICES AND SYSTEMS FOR THE DELIVERY OF ACTIVE AGENTS
CN106604755B (en) 2014-06-30 2020-08-11 Syqe医药有限公司 Flow-regulated inhaler device
KR102561375B1 (en) 2014-06-30 2023-08-01 사이키 메디컬 엘티디. Clamping chamber for clamping inhaler dose cartridge
IL273507B2 (en) * 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for pulmonary delivery of active agents
WO2016001921A2 (en) 2014-06-30 2016-01-07 Syqe Medical Ltd. Method and device for vaporization and inhalation of isolated substances
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
ES2874087T3 (en) 2016-01-06 2021-11-04 Syqe Medical Ltd Low-dose therapeutic treatment
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
US20220241239A1 (en) * 2019-07-17 2022-08-04 Zealand Pharma A/S Pharmaceutical composition for subcutaneous administration
US12453757B2 (en) * 2022-11-28 2025-10-28 New York Institute Of Technology Method for ameliorating autism symptoms by pharmacological activation of the neurotensin receptor 1 (NTSR1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140786A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008040361A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of a combination of hypothermia inducing drugs
WO2008040360A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140786A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008040361A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of a combination of hypothermia inducing drugs
WO2008040360A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
APPENDINO G ET AL: "TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 13, no. 12, 1 December 2003 (2003-12-01), pages 1825 - 1837, XP002487646, ISSN: 1354-3776 *
BONFILS P K ET AL: "Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB LNKD- DOI:10.1016/J.NEUINT.2006.03.015, vol. 49, no. 5, 1 October 2006 (2006-10-01), pages 508 - 518, XP025067906, ISSN: 0197-0186, [retrieved on 20061001] *
DING ET AL: "Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1065, no. 1-2, 14 December 2005 (2005-12-14), pages 147 - 151, XP005206563, ISSN: 0006-8993 *
LEKER RONEN R ET AL: "Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US LNKD- DOI:10.1161/01.STR.0000079817.68944.1E, vol. 34, no. 8, 1 August 2003 (2003-08-01), pages 2000 - 2006, XP002451424, ISSN: 0039-2499 *
MAULER FRANK ET AL: "BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury", CNS DRUG REVIEWS, BRANFORD, CT, US, vol. 9, no. 4, 1 January 2003 (2003-01-01), pages 343 - 358, XP002451422, ISSN: 1080-563X *
PEGORINI S ET AL: "Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS, vol. 144, 1 January 2005 (2005-01-01), pages 727 - 735, XP007904383, ISSN: 0007-1188 *

Also Published As

Publication number Publication date
WO2010015260A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
WO2010015260A3 (en) Administration by infusion for the treatment of ischemic effects
MX2009003469A (en) Use of hypothermia inducing drugs to treat ischemia.
WO2008040361A3 (en) Use of a combination of hypothermia inducing drugs
MY148496A (en) Dpp iv inhibitor formulations
MX2009012000A (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis.
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
NZ588913A (en) Liver cancer drug
BRPI0922796A2 (en) PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION AND MANUFACTURING METHOD
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
WO2009124552A3 (en) Use of a combination of hypothermia inducing drugs
MX2010001236A (en) 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators.
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
WO2009071094A3 (en) Combination treatment of ischemic effects
MX2009011900A (en) Diabetic wound healing.
WO2009138186A3 (en) SEQUENTIAL ADMINISTRATION OF 20,20,21,21-PENTAFLUORO-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIENE-3-ONE AND ONE OR MORE PROGESTATIONAL HORMONES FOR TREATING GYNAECOLOGICAL DISEASES
WO2009071096A3 (en) Combination of medical and physical cooling treatment of ischemic effects
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
AR063497A1 (en) PIRRODINIL COMPOUND -2-ONA, INTERMEDIARY FOR THE SYNTHESIS OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT
ZA200904704B (en) Treatment of cachexia
MX2009011576A (en) New 4,8-diphenyl-polyazanaphthalene derivatives.
WO2007047575A3 (en) Pharmacological treatments for sleep-related breathing disorders
NO20061515L (en) Use of oxcarbazepine for the treatment of diabetic neurpathic pain and improvement of sleep
WO2009124551A3 (en) Use of vanilloid receptor agonists as hypothermia inducing drugs for the treatment of ischemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09776255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09776255

Country of ref document: EP

Kind code of ref document: A2